Truist Financial Initiates a Buy Rating on Viridian Therapeutics (VRDN)
I'm PortAI, I can summarize articles.
Truist Financial analyst initiates a Buy rating on Viridian Therapeutics (VRDN) with a price target. TD Cowen's Joseph Thome also issued a Buy rating on November 21. However, TR | OpenAI reiterated a Hold rating on November 13. TipRanks offers a Black Friday sale on its Premium service for investment insights.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments